Fundraising FoxGeneius Biotechnology
Natick, US · Founded 2015 · Delaware corporation
Find your way into Geneius Biotechnology
Sign up to see every warm intro you have to Geneius Biotechnology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Geneius Biotechnology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Geneius develops and commercializes autologous adoptive T-cell therapies designed to treat cancer by targeting the mutations driving a patient's disease. The company aims to deliver its immunotherapy through community oncologists at a lower cost than CAR-T, in the oncology/immunotherapy space.
Founders & leadership
Geneius Biotechnology was founded in 2015 by Alfred Slanetz.
Board
RM
Ryan M. LaneBoard director
Reported raises · per SEC filings
Form D private placements$8.3M disclosed across 4 rounds · 2015–2017
▶$550KraisedSep 2018 · 7 investors · BiotechnologyRule 506(b)
▶$550KraisedSep 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alfred E. SlanetzExecutive Officer, Director
- Steven KloeblenDirector
- Offering amount
- $5M
- Amount sold
- $550K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.4MraisedJan 2016 · 20 investors · BiotechnologyRule 506(b)
▶$2.4MraisedJan 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alfred SlanetzExecutive Officer, Director
- Ryan LaneDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Sales commissions
- $70K
- Placement agents
- Roth Capital Partners
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.1MraisedJun 2015 · 45 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJun 2015 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan LaneDirector
- Alfred SlanetzExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- Sales commissions
- $45K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.3MraisedMar 2015 · 34 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2015 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan M. LaneDirector
- Alfred SlanetzExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.3M
- Sales commissions
- $210K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Amicus TherapeuticsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Geneius Biotechnology.
Frequently asked questions
- What does Geneius Biotechnology do?
- Geneius develops and commercializes autologous adoptive T-cell therapies designed to treat cancer by targeting the mutations driving a patient's disease. The company aims to deliver its immunotherapy through community oncologists at a lower cost than CAR-T, in the oncology/immunotherapy space.
- Who founded Geneius Biotechnology?
- Geneius Biotechnology was founded by Alfred Slanetz in 2015.
- How much funding has Geneius Biotechnology raised?
- Geneius Biotechnology has disclosed $8.3M raised across 4 rounds.
- Where is Geneius Biotechnology headquartered?
- Geneius Biotechnology is headquartered in Natick, US.